Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Investor Presentation (September 2016)
17 slides from Actinogen Medical's investor presentation, Sep 21, 2016
Slide 1: Understanding Alzheimer's
Understanding Alzheimer's Dr. Bill Ketelbey CEO & Managing Director
Slide 2: Alzheimer's disease is emerging as the most significant health challenge of our time
Alzheimer’s disease is emerging as the most significant health challenge of our time 30% of 85 year olds 47m 75m 132m One person Total cost rise have Alzheimer’s Disease every 3 seconds to US$2 trillion Numbers will by 2030 1 in 3 seniors will die double every Globally there with Alzheimer’s 20 year
Slide 3: Meet Mary
Meet Mary • Late 80’s • Early Alzheimer's disease, otherwise generally quite well • On Aricept for the past 6 months which provided reasonable symptomatic benefit • Responded quite well initially, but the response has plateaued and has now begun to decline • No clear alternate or additional medicati
Slide 4: Alzheimer's Drug-Development Pipeline: 2016
Alzheimer’s Drug-Development Pipeline: 2016 Source: clinicaltrials.gov as at Jan 4th, 2016 93 agents • 74% biopharma sponsored • 50% amyloid targeted 60 50 40 30 20 10 0 Trial Data Phase I Phase II Phase III Source: Cummings, J., Morstorf, T., & Lee, G. (2016) 4
Slide 5: Research Drug to Medicines
Research Drug to Medicines $ Academia Government grants Philanthropy Biotech companies Pharmaceutical companies 5
Slide 6: The Long Road to a New Medicine
The Long Road to a New Medicine Source: www.google.com.au 6
Slide 7: Drug Discovery – 15 years, $1.5bn, <0.01% success!
Drug Discovery – 15 years, $1.5bn, <0.01% success! Source: Pharmaceutical Research and Manufacturers of America 7
Slide 8: Actinogen's journey of discovery
Actinogen’s journey of discovery Xanamem™ Xanamem™ crosses blood data publication 11ẞ-HSD1 is highly brain barrier Carbenoxolone is shown First and presentation expressed in regions to enhance cognitive First important for cognition patent human at major function in elderly men filed and type II dia
Slide 9: Xanamem™: Targeting elevated cortisol at the site of action
Xanamem™: Targeting elevated cortisol at the site of action 9
Slide 10: Recent publications confirm association between cortisol and Alzheimer's
Recent publications confirm association between cortisol and Alzheimer’s Plasma cortisol, brain amyloid-β, and cognitive decline in preclinical Alzheimer's disease: A 6-year prospective cohort study. Pietrzak et al. 2016 for the AIBL Research Group, Australia, US Dept. of Veterans Affairs and Yale M
Slide 11: Plasma cortisol, amyloid-β, and cognitive decline in preclinical Alzheimer's disease
Plasma cortisol, amyloid-β, and cognitive decline in preclinical Alzheimer's disease: A 6-year prospective cohort study Robert H Pietrzak1,2, Simon M Laws3,4, Yen Ying Lim5, Sophie J Bender6, Tenielle Porter3,4, James Doecke7, David Ames8,9, Christopher Fowler5, Colin L Masters5, Lidija Milicic4, St
Slide 12: Xanamem development: proposed study design
Xanamem development: proposed study design XanADu – Phase II double blind, randomised, placebo-controlled study to assess the efficacy of Xanamem™ in participants with mild AD 220 Co-primary end points Treatment course ADAS-Cog 12 weeks Mild Alzheimer’s patients ADCOMS + Final Xanamem™ Being triall
Slide 13: ACW financials
ACW financials Key Corporate Data Market Cap* ~AU$36 million Public company listed on the Entity Australia Stock Exchange (ACW) Share Price* AU$0.06 Shares on issue^ ~606 million Cash position** AU$7.53m Ownership by top 20 55% *market cap and share price data as at 29th Aug 2016 post placement an
Slide 14: Alzheimer's Deal Valuations
Alzheimer’s Deal Valuations High potential for Phase I and II Assets Deals signed 2005-2015, selected for Alzheimer’s as a lead indication Source Medtracker: *Data limitation – analysis set contains only those cases that have specified development stage at time of deal. 14
Slide 15: Mary is my mother….your mother…aunt… neighbour….
Mary is my mother….your mother…aunt… neighbour…. $ Academia Government grants Philanthropy Biotech companies Pharmaceutical companies 15
Slide 16: THANK YOU
THANK YOU [Astinogen 5
Slide 17: Focusing on an innovative approach for treating Alzheimer's
Focusing on an innovative approach, through the inhibition of cortisol production, for treating Alzheimer's disease and cognitive impairment in chronic neurodegenerative and metabolic diseases.
Actinogen Medical — Investor Presentation (September 2016) on 6ix